Moermond, Caroline T. A. https://orcid.org/0000-0002-9770-7023
Ă…gerstrand, Marlene https://orcid.org/0000-0003-2697-2310
Backhaus, Thomas https://orcid.org/0000-0001-9643-1662
Cannata, Cristiana https://orcid.org/0000-0002-6856-0106
Davidson, Todd https://orcid.org/0000-0002-3171-1193
Faber, Melvin https://orcid.org/0009-0002-6702-8991
Janer, Gemma https://orcid.org/0000-0001-6229-425X
Maack, Gerd https://orcid.org/0000-0001-5980-6533
Ragas, Ad https://orcid.org/0000-0002-6200-6366
Smit, Els https://orcid.org/0000-0002-1090-1684
Woelz, Jan https://orcid.org/0009-0009-2454-6327
Maynard, Samuel K. https://orcid.org/0000-0001-6099-9176
Funding for this research was provided by:
PREMIER Project , IMI JU2 (875508)
Article History
Received: 27 February 2026
Accepted: 26 May 2026
First Online: 4 June 2026
Declarations
:
: Not applicable.
: Not applicable.
: Samuel Maynard is employed by AstraZeneca, a marketing authorization holder of the case study compound metoprolol.